Tate & Lyle PLC
Public consensus - Last updated
17/10/24
Contributors
- 8 FY25 - Continuing based on
|
Reporting currency:
GBP
Reporting unit: Millions | NO. OF FORECASTS | FY25 CONSENSUS 17/10/24 | FY25 - Continuing MEDIAN | FY25 - Continuing MIN | FY25 - Continuing MAX |
|---|---|---|---|---|---|
| Volume change (%) | |||||
| Volume change - Food & Beverage Solutions | |||||
Total Food & Beverage Solutions | 8 | 5 | 4 | 3 | 7 |
| Volume change - SPLENDA® Sucralose | |||||
SPLENDA® Sucralose | 8 | 1 | 1 | - | 3 |
| Volume change - Primary Products Europe | |||||
Primary Products Europe | 7 | (17) | (15) | (25) | (7) |
| Group Income Statement (£m) | |||||
| Revenue - Food & Beverage Solutions | |||||
Food & Beverage Solutions | 8 | 1,319 | 1,323 | 1,265 | 1,365 |
| Revenue - Sucralose | |||||
Sucralose | 8 | 171 | 171 | 166 | 176 |
| Revenue - Primary Products Europe | |||||
Primary Products Europe | 8 | 86 | 89 | 65 | 97 |
Revenue - Continuing Operations | 8 | 1,576 | 1,581 | 1,528 | 1,606 |
| Adjusted EBITDA | |||||
Food & Beverage Solutions | 8 | 296 | 294 | 290 | 305 |
Sucralose | 8 | 52 | 52 | 48 | 53 |
Primary Products Europe | 8 | (4) | (4) | (6) | (2) |
Adjusted EBITDA - Continuing Operations | 8 | 343 | 343 | 336 | 354 |
Less: Depreciation and adjusted amortisation | 8 | (72) | (71) | (76) | (70) |
Adjusted operating profit - Continuing Operations | 8 | 271 | 270 | 262 | 279 |
Net finance expense | 8 | (5) | (5) | (8) | (1) |
Adjusted share of profit of joint venture | 7 | - | - | - | - |
Adjusted profit before tax - Continuing Operations | 8 | 266 | 267 | 255 | 276 |
Adjusted Profit after Tax - Continuing Operations (pre excepts and amort) | 8 | 211 | 209 | 201 | 230 |
Average diluted shares (m) (including impact of share buyback) | 8 | 386.9 | 387.7 | 372.3 | 394.2 |
Adjusted diluted EPS (p) - continuing | 8 | 54.6 | 53.9 | 51.8 | 58.9 |
Dividend/Share (p) | 7 | 20.5 | 20.1 | 19.0 | 22.9 |
$/£ assumption (average rate) | 6 | 1.28 | 1.29 | 1.26 | 1.30 |
€/£ assumption (average rate) | 6 | 1.18 | 1.18 | 1.18 | 1.19 |
| Group Cash Flow Statement (£m) | |||||
Adjusted Free cash flow (before exceptional cash flows) | 8 | 161 | 167 | 101 | 205 |
Disclaimer
Tate & Lyle PLC (“Tate & Lyle”) invites registered sell-side analysts that monitor Tate & Lyle’s stock to submit their forecasts to an external, web-based tool managed
by Vuma Financial Limited (“Vuma”), a company independent of Tate & Lyle.
The web-based tool generates an aggregation of publicly available forecasts collated exclusively by Vuma, but only on the basis of information submitted by those
analysts who choose to participate. The arithmetic average of the constituent analyst forecasts is known as “Consensus”. Vuma has no access to Tate & Lyle's
internal forecasts, budgets or any other information which is not publicly available.
Tate & Lyle has not commented on individual forecasts nor does it intend to do so in the future. Tate & Lyle assumes no obligation to update or revise such
information and nothing in this analysis should be taken as a recommendation to buy or sell shares in Tate & Lyle or to take any other action or place any reliance
on the analysis.
Consensus figures are provided for information only, and neither Tate & Lyle nor any of its subsidiary undertakings nor any director, officer or employee of
Tate & Lyle or any of its subsidiary undertakings accepts any responsibility for the accuracy or completeness of forecasts used in this analysis and therefore shall
have no liability whatsoever for the consequences of any reliance or actions taken or not taken based on any of the information in this analysis.
by Vuma Financial Limited (“Vuma”), a company independent of Tate & Lyle.
The web-based tool generates an aggregation of publicly available forecasts collated exclusively by Vuma, but only on the basis of information submitted by those
analysts who choose to participate. The arithmetic average of the constituent analyst forecasts is known as “Consensus”. Vuma has no access to Tate & Lyle's
internal forecasts, budgets or any other information which is not publicly available.
Tate & Lyle has not commented on individual forecasts nor does it intend to do so in the future. Tate & Lyle assumes no obligation to update or revise such
information and nothing in this analysis should be taken as a recommendation to buy or sell shares in Tate & Lyle or to take any other action or place any reliance
on the analysis.
Consensus figures are provided for information only, and neither Tate & Lyle nor any of its subsidiary undertakings nor any director, officer or employee of
Tate & Lyle or any of its subsidiary undertakings accepts any responsibility for the accuracy or completeness of forecasts used in this analysis and therefore shall
have no liability whatsoever for the consequences of any reliance or actions taken or not taken based on any of the information in this analysis.